american
tegumentari
leishmaniasi
atl
vector
born
diseas
caus
brazil
mainli
leishmania
viannia
braziliensi
intracellular
pathogen
uniqu
leishmania
speci
caus
spectrum
clinic
present
rang
selfheal
benign
cutan
lesion
cl
sever
form
mucos
leishmaniasi
ml
ml
common
cl
affect
approxim
patient
infect
almost
exclus
l
braziliensi
indic
host
intrins
factor
predispos
sever
outcom
infect
profoundli
influenc
balanc
effector
regulatori
specif
tcell
respons
higher
immunorespons
leishmani
antigen
account
worsen
prognosi
diseas
suscept
infecti
diseas
influenc
genet
background
suppos
effici
activ
cellular
immun
respons
specif
axi
might
play
key
role
protect
leishmaniasi
cytokin
interferongamma
tumor
necrosi
factor
alpha
major
role
control
intracellular
growth
etiolog
pathogen
suitabl
amount
produc
subclin
cl
patient
proven
import
mediat
cure
express
cytokin
gener
consequ
exacerb
immun
respons
induc
intens
patholog
damag
observ
ml
importantli
clinic
cure
ml
directli
relat
decreas
level
despit
even
longterm
cure
ml
patient
still
produc
higher
level
cl
indic
individu
maintain
abil
continu
produc
signific
amount
cytokin
interestingli
high
low
produc
clearli
seen
among
cure
ml
patient
data
suggest
genet
factor
potenti
drive
secret
upon
leishmani
stimuli
potenti
determin
clinic
evolut
even
predisposit
sever
form
diseas
singl
nucleotid
polymorph
snp
locat
first
intron
human
gene
end
adjac
ca
repeat
region
polymorph
put
influenc
secret
analysi
biolog
role
snp
suggest
carrier
low
produc
find
explain
high
frequenc
allel
eventu
associ
suscept
tuberculosi
differ
popul
howev
snp
still
controversi
issu
regard
risk
acquir
tuberculosi
sinc
associ
suscept
diseas
demonstr
author
even
larger
ethnic
differ
popul
studi
suscept
infecti
diseas
like
sever
acut
respiratori
syndrom
sar
also
describ
suggest
variabl
product
link
snp
possibl
play
major
role
suscept
infecti
diseas
especi
intracellular
pathogen
previou
report
shown
polymorph
locat
promot
higher
frequenc
among
ml
patient
data
avail
genotyp
analysi
atl
conceiv
allel
variant
gene
may
influenc
level
releas
protein
turn
could
increas
suscept
leishmaniasi
predispos
progress
mucos
leishmaniasi
aim
investig
whether
gene
increas
risk
develop
cutan
mucos
leishmaniasi
well
determin
whether
high
low
leishmaniainduc
product
associ
exist
polymorph
total
leishmaniasi
patient
enrol
studi
seventyeight
cl
patient
male
femal
mean
age
sd
year
ml
male
femal
mean
age
sd
year
includ
patient
refer
endem
area
l
braziliensi
infect
state
rio
de
janeiro
brazil
diagnost
criteria
base
clinic
parasitolog
immunolog
paramet
describ
elsewher
patient
reexamin
one
year
end
therapi
consid
clinic
cure
moment
studi
total
healthi
individu
femal
male
geograph
area
rio
de
janeiro
brazil
involv
studi
written
inform
consent
obtain
individu
accord
protocol
approv
ethic
committe
human
research
oswaldo
cruz
brazilian
ministri
health
genom
dna
extract
use
commerci
kit
dnazol
dnazol
invitrogen
life
technolog
gaithersburg
md
usa
accord
manufactur
instruct
genotyp
region
first
intron
gene
carri
amplif
refractori
mutat
system
armspcr
reaction
amplif
allel
describ
previous
pbmc
total
patient
ml
cl
obtain
ficollhypaqu
densiti
centrifug
cell
per
well
stimul
vitro
crude
extract
l
braziliensi
promastigot
antigen
describ
previous
supernat
recov
measur
elisa
monoclon
antibodi
recombin
cytokin
purchas
pharmingen
san
diego
ca
usa
procedur
perform
accord
manufactur
instruct
sampl
test
duplic
concentr
analyz
use
program
life
scienc
edit
molecular
devic
corpor
usa
result
express
picogram
per
millilit
pgml
minimum
level
detect
pgml
casecontrol
studi
analyz
use
logist
regress
model
correct
sex
covari
perform
statist
softwar
r
foundat
statist
comput
version
result
obtain
quantit
variabl
analyz
oneway
analysi
varianc
anova
tukeykram
posttest
use
graphpad
prism
version
window
graphpad
softwar
san
diego
ca
usa
genotyp
allel
frequenc
healthi
control
well
group
patient
divid
clinic
form
atl
shown
tabl
popul
found
hardyweinberg
equilibrium
locu
analys
use
genotyp
allel
frequenc
compar
patient
control
demonstr
associ
suscept
protect
atl
per
se
p
genotyp
p
allel
way
associ
sever
mucos
form
found
compar
cl
case
p
despit
lower
frequenc
tt
genotyp
among
atl
comparison
aa
ta
patient
statist
differ
observ
comparison
control
among
patient
popul
inde
low
frequenc
tt
genotyp
compar
one
alreadi
expect
gener
popul
control
individu
analysi
product
upon
leishmania
antigen
stimul
show
expect
differ
secret
cl
ml
signific
p
order
evalu
function
influenc
snp
product
mean
sd
observ
clinic
form
atl
comparison
leishmani
induc
cytokin
level
produc
genotyp
carriedout
figur
ml
patient
similar
level
produc
independ
ifng
genotyp
p
aa
pgml
median
pgml
n
ta
pgml
median
pgml
n
tt
pgml
median
pgml
n
addit
ml
patient
clearli
p
separ
two
group
accord
level
product
high
pgml
pgml
n
low
pgml
pgml
n
profil
produc
observ
indistinct
among
aa
ta
genotyp
hand
cl
patient
present
signific
differ
product
compar
among
patient
three
ifng
genotyp
p
detect
valu
lower
individu
pgml
median
pgml
n
moder
pgml
median
pgml
n
high
pgml
n
postest
indic
signific
differ
observ
p
cl
ml
valu
minimum
detect
level
great
deal
evid
indic
suscept
leishmaniasi
infecti
diseas
relat
genet
variabl
cytokin
loci
exposit
l
braziliensi
host
acquir
infect
without
develop
diseas
progress
sever
stage
mild
cl
sever
ml
diseas
l
braziliensi
infect
downmodul
type
respons
predispos
develop
cl
higher
level
observ
associ
mucos
diseas
result
indic
ifng
snp
associ
develop
leishmaniasi
per
se
progress
sever
form
howev
decreas
frequenc
homozyg
tt
genotyp
observ
cl
also
ml
patient
compar
control
tabl
associ
reduc
homozyg
frequenc
chronic
diseas
also
observ
sicilian
tuberculosi
patient
hand
snp
seem
impact
vitro
product
cl
allel
associ
higher
level
cytokin
expect
ifng
polymorph
cure
cl
case
exhibit
aa
genotyp
present
significantli
lower
amount
leishmaniastimul
level
tatt
genotyp
similar
result
obtain
activ
tuberculosi
patient
profil
maintain
even
month
clinic
cure
indic
intrins
patient
abil
produc
affect
due
still
controversi
role
snp
influenc
outcom
intracellular
infect
possibl
larger
differ
popul
eg
brazilian
endem
area
would
show
posit
relationship
either
sever
suscept
leishmaniasi
shown
tuberculosi
patient
ml
case
differ
product
observ
among
ifng
genotyp
possibl
exacerb
respons
observ
ml
even
clinic
cure
presenc
absenc
allel
affect
level
associ
observ
time
cure
therapi
level
product
howev
rule
hypothesi
longer
period
ill
may
induc
patient
sustain
hyperrespons
leishmani
antigen
due
chronic
parasit
activ
nevertheless
presenc
per
se
also
secret
level
other
cytokin
like
constitut
key
factor
immunoregul
hostparasit
relationship
demonstr
mani
genom
variat
locat
other
candid
gene
contribut
phenotyp
express
taken
togeth
result
reinforc
idea
ifng
snp
function
role
regul
gene
respons
intracellular
pathogen
howev
hypothes
depend
immunopathogen
characterist
influenc
clinic
statu
patient
cl
ml
differ
signal
pathway
activ
induc
distinct
transcript
factor
lead
consequ
differenti
level
product
similar
stimul
condit
despit
caus
leishmania
speci
cl
ml
patient
distinct
immunoregulatori
mechan
induc
parasit
explain
differ
pathogenesi
therapeut
respons
mayb
prognosi
diseas
complex
interact
occur
parasit
infect
predict
clinic
cours
diseas
could
explain
uniqu
mechan
result
demonstr
ifng
snp
could
involv
pathogenesi
leishmaniasi
influenc
amount
releas
cl
patient
although
could
prevent
diseas
develop
possibl
ml
case
potenti
polymorph
regulatori
gene
also
involv
turn
influenc
product
singl
nucleotid
polymorph
snp
interferongamma
tumor
necrosi
factor
alpha
interleukin
american
tegumentari
leishmaniasi
atl
cutan
leishmaniasi
cl
mucos
leishmaniasi
ml
peripher
blood
mononuclear
cell
pbmc
amplif
refractori
mutat
systempolymeras
chain
reaction
armspcr
standard
deviat
sd
author
declar
compet
interest
author
commerci
associ
might
pose
conflict
interest
author
read
approv
final
manuscript
gim
cjc
mom
amc
contribut
equal
studi
design
data
collect
experiment
procedur
interpret
result
manuscript
elabor
rcb
ag
fm
vm
particip
data
collect
experiment
procedur
vsa
mpon
msm
amc
respons
clinic
evalu
cp
ep
particip
studi
design
help
draft
manuscript
prepubl
histori
paper
access
